Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma

Inclusion criteria for localized RCC treated with partial nephrectomy To be considered eligible to participate in this study, a patient must meet all the inclusion criteria listed below: * ≥ 18 years of age. * Have primary or suspected diagnosis of RCC, with presence of cT1-2 renal mass by diagnostic CT assessment. * Scheduled for partial nephrectomy of renal mass. * Expected survival of at least 3 months. * Written informed consent available. * ECOG ≤ 1 (Appendix G). * Negative serum or urine pregnancy test within 24 hours for females of child bearing age * Recovered from toxicity of any prior therapy to ≥ grade 1. Inclusion criteria for advanced RCC treated with radical nephrectomy To be considered eligible to participate in this study, a patient must meet all the inclusion criteria listed below: * ≥ 18 years of age. * Have pathologic or suspected diagnosis of RCC with presence of cT1-4 renal mass and evidence of nodal or metastatic involvement by diagnostic CT assessment * Scheduled for radical nephrectomy and lymph node dissection. * Expected survival of at least 3 months. * ECOG ≤ 2. * Negative serum or urine pregnancy test within 24 hours for females of child bearing age. * Recovered from toxicity of any prior therapy to ≥ grade 1 * Written informed consent available. Exclusion criteria for both localized and advanced RCC * History of any anaphylactic reaction, any severe allergy, or any allergy to folate. * Brain metastases * Baseline GFR \< 50 mL/min/1.73m2) * Hepatic toxicity ≥ Grade 2 (using CTCAE version 4 standard definitions). * Participation in another investigational drug trial either concurrently or 30 days prior to surgery * Any medical condition that in the opinion of the investigators could potentially jeopardize the safety of the patient, limit the patient's ability to complete the study, and/or compromise the objectives of the study. * Known sensitivity to fluorescent light